Asset Details
Do you wish to reserve the book?
Deep-Brain Stimulation for Parkinson's Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Deep-Brain Stimulation for Parkinson's Disease
Do you wish to request the book?
Deep-Brain Stimulation for Parkinson's Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Deep-Brain Stimulation for Parkinson's Disease
2012
Overview
A 72-year-old man with Parkinson's disease is referred for consideration of deep-brain stimulation, which involves the implantation of electrodes in one of the nuclei of the basal ganglia and can result in significant improvement in some symptoms of Parkinson's disease.
Foreword
This
Journal
feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the author's clinical recommendations.
Stage
A 72-year-old right-handed man with a 12-year history of Parkinson's disease presents with a diminished response to medication and right-sided dyskinesia (involuntary movements). During the past several years, he has been taking multiple drugs for Parkinson's disease, including a monoamine oxidase inhibitor, amantadine, a dopamine agonist, and carbidopa–levodopa. He reports that with his current regimen, which includes 1.5 tablets of 25/100 carbidopa–levodopa taken every 2 hours, he has marked reductions in tremor, rigidity, and bradykinesia and substantial improvement in his walking. Despite multiple interval and dose adjustments, however, he also reports 6 hours per day of “off” time, when . . .
Publisher
Massachusetts Medical Society
Subject
Adult and adolescent clinical studies
/ Aged
/ Antiparkinson Agents - therapeutic use
/ Biological and medical sciences
/ Deep Brain Stimulation - adverse effects
/ Deep Brain Stimulation - instrumentation
/ Deep Brain Stimulation - methods
/ Humans
/ Male
/ Organic mental disorders. Neuropsychology
/ Parkinson Disease - drug therapy
/ Parkinson Disease - physiopathology
/ Patients
/ Practice Guidelines as Topic
